STOCK TITAN
  1. Home
  2. News
  3. ZYME

Zymeworks Inc. - ZYME STOCK NEWS

Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company's mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases.

Zymeworks specializes in developing best-in-class bi-specific antibodies and antibody-drug conjugates (ADCs) to treat oncology, autoimmunity, and inflammatory diseases. Their proprietary platforms, including Azymetric™, Albucore™, and ZymeLink™, enable the creation of highly potent bi-specific antibodies and multivalent protein therapeutics targeting a range of indications.

The company's leading therapeutic candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently in multiple Phase 1, Phase 2, and pivotal clinical trials globally. Zanidatamab is being developed as a targeted treatment for patients with HER2-expressing cancers. Recent milestones include the acceptance of a Biologics License Application (BLA) by the FDA and China's National Medical Products Administration (NMPA) for second-line treatment of HER2-positive biliary tract cancers (BTC).

Zymeworks is also advancing a deep preclinical pipeline, including candidates like zanidatamab zovodotin (ZW49) and new investigational drugs ZW171 and ZW191, with plans for multiple IND filings in 2024 and 2025. The company is financially robust, with a cash runway extending into the second half of 2027, bolstered by strategic partnerships with BeiGene and Jazz Pharmaceuticals, among others.

The company's complementary therapeutic platforms and fully integrated drug development engine enable precise engineering of differentiated product candidates, offering potential best-in-class treatments for various challenging diseases. For more information, visit www.zymeworks.com.

News

Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary
Zymeworks Inc. (ZYME) will participate in investor conferences to showcase its diverse pipeline of biotherapeutics for difficult-to-treat diseases. The company will present at TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
conferences
-
News

Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call

Rhea-AI Summary
Zymeworks Inc. (ZYME) will report its Q4 2023 financial results on March 6, 2024, followed by a conference call and webcast to discuss financial results and corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences earnings
-
News

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

Rhea-AI Summary
Zymeworks Inc. announced the appointment of Dr. Alessandra Cesano to its board of directors, succeeding Dr. Kenneth Hillan. Dr. Cesano brings over 25 years of experience in drug development, diagnostics, and cancer immunology. She will help advance the company's pipeline of novel antibody-drug conjugates and multispecific antibodies. Dr. Cesano currently serves as a director at Puma Biotechnology and Summit Therapeutics, and as the Chief Medical Officer of ESSA Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
management
News

Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary
Zymeworks Inc. (ZYME) announced its participation in upcoming investor conferences, including Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, Oppenheimer 34th Annual Healthcare Life Sciences Conference, and Citi's 2024 Virtual Oncology Leadership Summit. The company aims to present its diverse pipeline of novel biotherapeutics for difficult-to-treat diseases, with the management participating in one-on-one meetings and fireside chats. The presentations and webcasts will be available on Zymeworks’ website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
-
News

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) provided an update on key strategic priorities for 2024 and 2025, highlighting a cash runway into 2H 2027, top-line data readout from a Phase 3 trial, regulatory reviews for zanidatamab, and progression on their R&D portfolio. The company also announced additional leadership appointments and a presentation at the J.P. Morgan 42nd Annual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
-
News

Zymeworks Announces Additional Leadership Appointments

Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) announced significant additions to its leadership team, promoting Dr. Jeffrey Smith to Executive Vice President and Chief Medical Officer, Dr. John Fann to Senior VP, Process Sciences, and appointing seven new Vice Presidents. The company emphasizes its commitment to nurturing internal talent and strengthening its capabilities and experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
News

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) has entered into a securities purchase agreement with EcoR1 Capital, LLC for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock. The proceeds from this transaction are expected to extend the company's cash runway into H2 2027, providing financial support for the development of novel biotherapeutics and general corporate purposes. The aggregate gross proceeds from the offering are expected to be approximately $50 million, before deducting estimated offering expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
none
-
News

Zymeworks Added to Nasdaq Biotechnology Index

Rhea-AI Summary
Zymeworks Inc. (ZYME) is set to be added to the Nasdaq Biotechnology Index (NBI) on December 18, 2023. The NBI tracks the performance of biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market. Zymeworks' addition to the NBI reflects its eligibility and market performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
-
News

Zymeworks Announces Participation in Upcoming Investor Conference

Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) to participate in the 42nd Annual J.P. Morgan Healthcare Conference, with one-on-one meetings scheduled on January 8-11, 2024, and a corporate presentation on January 11th, 2024 at 8:15 am Pacific Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences
News

Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) reports 44% decrease in net loss for the first nine months of 2023, with cash resources of $390.2 million. Clinical results from Phase 1b/2 study of zanidatamab plus chemotherapy and tislelizumab presented at ESMO Annual Congress. ZW251, a GPC3 targeted antibody drug conjugate, anticipated for IND filing in 2H-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
earnings

FAQ

What is the current stock price of Zymeworks (ZYME)?

The current stock price of Zymeworks (ZYME) is $14.14 as of December 20, 2024.

What is the market cap of Zymeworks (ZYME)?

The market cap of Zymeworks (ZYME) is approximately 914.0M.

What is Zymeworks Inc.?

Zymeworks Inc. is a global biotechnology company focused on the discovery, development, and commercialization of novel, multifunctional biotherapeutics.

What are the key therapeutic platforms of Zymeworks?

Zymeworks' key therapeutic platforms include Azymetric™, Albucore™, and ZymeLink™, which are used to develop potent bi-specific antibodies and multivalent protein therapeutics.

What is zanidatamab?

Zanidatamab is Zymeworks' leading clinical candidate, a novel HER2-targeted bispecific antibody currently under evaluation in multiple global clinical trials for treating HER2-expressing cancers.

Which partnerships has Zymeworks formed for zanidatamab?

Zymeworks has partnerships with BeiGene and Jazz Pharmaceuticals to develop and commercialize zanidatamab in different territories.

What recent regulatory milestones has Zymeworks achieved?

Recent milestones include the acceptance of a Biologics License Application (BLA) by the FDA and China's NMPA for zanidatamab as a treatment for HER2-positive biliary tract cancer.

What financial outlook does Zymeworks have?

Zymeworks has a robust financial position with a cash runway extending into the second half of 2027, supported by strategic partnerships and recent private placements.

What are the current projects in Zymeworks' pipeline?

Current projects include the clinical development of zanidatamab, zanidatamab zovodotin (ZW49), and preclinical candidates ZW171 and ZW191, with multiple IND filings planned for 2024 and 2025.

How does Zymeworks' pipeline address unmet medical needs?

Zymeworks' pipeline focuses on developing therapies for difficult-to-treat cancers, offering potential best-in-class treatments that address significant unmet medical needs.

What is the role of Zymeworks' platforms in drug development?

Zymeworks' proprietary platforms enable the precise engineering of highly differentiated antibody-based therapeutics, facilitating the development of multifunctional biotherapeutics.

Where can I find more information about Zymeworks?

For more information about Zymeworks, visit their official website at www.zymeworks.com.

Stock ZYME logo
Zymeworks Inc.

Nasdaq:ZYME

ZYME Rankings

#2615 Ranked by Market Cap
N/A Ranked by Dividends

ZYME Stock Data

914.00M
66.64M
0.08%
101.32%
6.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MIDDLETOWN